Press

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Nov 28 • 5 min read

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Seyltx Inc. (“Seyltx”), a privately owned U.S. based drug development company, to acquire Algernon’s NP-120 (“Ifenprodil”) research program for USD $2M cash…

Clearmind Medicine Announces 1-for-30 Reverse Share Split

Nov 21 • 2 min read

Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced it will conduct a reverse share split of its…

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Nov 21 • 3 min read

MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma…

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

Nov 21 • 2 min read

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine. Under an agreement with the University of Waterloo, formulation development…

Optimi Health November 2023 Shareholder Update

Nov 20 • 6 min read

Dear Optimi Health Shareholders, We greatly appreciate your patience and unwavering support as we navigate the intricate landscape of building and expanding our psychedelic supply enterprise. Throughout 2023, our primary focus has remained centered in Princeton, British Columbia, Canada, operating under the regulatory oversight of Health Canada. Our dedicated efforts have revolved around the meticulous…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441